ArticleCancers2010
Serum tumor markers in pancreatic cancer-recent discoveries.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 61 citations in OpenAlex.
- Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations.Communications medicine · 2026Review
- Metabolomics and Biomarker Discovery.Advances in experimental medicine and biology · 2026Review
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer.Cell death & disease · 2025Review
- Improving predictive accuracy of early recurrence in pancreatic ductal adenocarcinoma: Role of postoperative serum tumor markers.World journal of gastrointestinal surgery · 2025Article
- Review
- Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy.Journal of medicinal chemistry · 2023Article
- Systemic Diseases and Gastrointestinal Cancer Risk.Journal of cancer & allied specialties · 2023Review
- Managing inoperable pancreatic cancer: the role of the pancreaticobiliary physician.Frontline gastroenterology · 2022Article
- Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives.Oncology letters · 2021Review
- An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer.Biochemical genetics · 2021Article
- Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer.World journal of gastroenterology · 2021Article
- Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management.World journal of gastroenterology · 2021Review
- Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.CA: a cancer journal for clinicians · 2020Review
- The efficacy of the combination of percutaneous transhepatic biliary drainage andJournal of contemporary brachytherapy · 2020Article
- Novel Autoantibody Signatures in Sera of Patients with Pancreatic Cancer, Chronic Pancreatitis and Autoimmune Pancreatitis: A Protein Microarray Profiling Approach.International journal of molecular sciences · 2020Article
- Single Nucleotide Polymorphism in Adiponectin Gene and Risk of Pancreatic AdenocarcinomaAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Proteomics Profiling of Pancreatic Cancer and Pancreatitis for Biomarkers Discovery.Journal of cell science & therapy · 2018Article
- Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer.World journal of clinical oncology · 2017Review
- Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer.Gastroenterology & hepatology · 2017Article
- Incidence and Mortality Risks of Cancer in Patients with Type 2 Diabetes: A Retrospective Study in Shanghai, China.International journal of environmental research and public health · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The low prevalence of pancreatic cancer remains an obstacle to the development of effective screening tools in an asymptomatic population. However, development of effective serologic markers still offers the potential for improvement of diagnostic capabilities, especially for subpopulations of patients with high risk for pancreatic cancer. The accurate identification of patients with pancreatic cancer and the exclusion of disease in those with benign disorders remain important goals. While clinical experience largely dismissed many candidate markers as useful markers of pancreatic cancer, CA19-9 continues to show promise. The present review highlights the development and the properties of different tumor markers in pancreatic cancer and their impact on the diagnostic and treatment of this aggressive disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.